{"id":"mydcombi-drug","safety":{"commonSideEffects":[{"rate":"10-20%","effect":"Diarrhea"},{"rate":"10-20%","effect":"Nausea"},{"rate":"5-10%","effect":"Vomiting"},{"rate":"5-10%","effect":"Abdominal pain"},{"rate":"5-10%","effect":"Leukopenia"},{"rate":"5-10%","effect":"Thrombocytopenia"},{"rate":"5-10%","effect":"Anemia"},{"rate":"5-10%","effect":"Hypertension"},{"rate":"5-10%","effect":"Hyperkalemia"},{"rate":"5-10%","effect":"Hyperuricemia"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"Mycophenolate mofetil inhibits inosine monophosphate dehydrogenase, an enzyme crucial for lymphocyte proliferation, while cyclosporine inhibits calcineurin, a key component of the T-cell activation pathway. This dual mechanism of action results in a synergistic immunosuppressive effect, reducing the risk of organ rejection in transplant patients.","oneSentence":"MydCombi Drug is a combination of mycophenolate mofetil and cyclosporine, which works by suppressing the immune system to prevent organ rejection.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:56:17.779Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Prevention of organ rejection in kidney transplant patients"}]},"trialDetails":[{"nctId":"NCT06366217","phase":"PHASE4","title":"Efficacy of the MydCombi on Pupillary Dilation in Pediatric and Adult Patients","status":"NOT_YET_RECRUITING","sponsor":"University of California, San Francisco","startDate":"2024-09-30","conditions":"Dilation, Pupil Reaction Absent","enrollment":100},{"nctId":"NCT03751631","phase":"PHASE3","title":"Safety and Efficacy of Phenylephrine 2.5%-Tropicamide 1% Microdose Ophthalmic Solution for Pupil Dilation","status":"COMPLETED","sponsor":"Eyenovia Inc.","startDate":"2018-11-15","conditions":"Mydriasis","enrollment":70}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"MydCombi Drug","genericName":"MydCombi Drug","companyName":"University of California, San Francisco","companyId":"university-of-california-san-francisco","modality":"Small molecule","firstApprovalDate":"","aiSummary":"MydCombi Drug is a combination of mycophenolate mofetil and cyclosporine, which works by suppressing the immune system to prevent organ rejection. Used for Prevention of organ rejection in kidney transplant patients.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}